Antithrombin and D-dimer in predicting pregnancy complications in the 3rd trimester of pregnancy

doi:10.3969/j.issn.1673-8640.2018.10.011

Abstract

Abstract:

Objective To investigate the roles of antithrombin（AT） and D-dimer（DD） in predicting pregnancy complications in the 3rd trimester of pregnancy. Methods A total of 5 095 pregnant women were enrolled. Women in the 3rd trimester of pregnancy were included,while women with primary hypertension,diabetes mellitus,cardiac diseases,chronic nephrosis and chronic hepatopathy before pregnancy and women terminating pregnancy due to fetal chromosome abnormality were excluded. The levels of AT and DD in patients with and without pregnancy complications were compared,and Logistic regression analysis was used for evaluating the roles of AT and DD in predicting pregnancy complications. Results The maternal complications of 5 095 pregnant women during the 28th-40th gestational weeks in this study included 353 cases of preeclampsia,105 cases of intrahepatic cholestasis during pregnancy（ICP）,88 cases of gestational diabetes mellitus,45 cases of stillbirth and 15 cases of deep vein thrombosis（DVT）. There were 4 548 pregnant women without pregnancy complications. The level of DD in patients with pregnancy complications was higher than that without pregnancy complications（P<0.05）. The level of AT in patients with preeclampsia was lower than that without pregnancy complications（P<0.05）. The level of AT in patients with ICP was higher than that without pregnancy complications（P<0.05）. Compared with pregnant women without pregnancy complications,patients with ICP and stillbirth were younger,while those with gestational diabetes mellitus were elder（P<0.05）. The odds ratio （OR） of ICP for patients with AT>115% was 20.24 [95% confidence interval （CI）12.870-31.819]. The OR of preeclampsia for patients with AT<70% was 5.41（95%CI 3.72-7.87）. The OR of DVT for patients with DD>3.98 μg/mL was 5.74（95%CI 2.03-16.20）,that of stillbirth was 4.05（95%CI 2.16-7.52）,that of ICP was 2.95（95%CI 1.73-5.02）,and that of preeclampsia was 2.76（95%CI 2.01-3.81）. Conclusions AT and DD can predict pregnancy complications in the 3rd trimester of pregnancy.

Key words: Antithrombin, D-dimer, Pregnancy complications

CLC Number:

R446.1

LI Qin, ZHANG Chi, FEI Yang, TANG Ning. Antithrombin and D-dimer in predicting pregnancy complications in the 3rd trimester of pregnancy[J]. Laboratory Medicine, 2018, 33(10): 920-923.

Figures/Tables 2

References 12

[1]	SIMCOX L E,ORMESHER L,TOWER C,et al.Thrombophilia and pregnancy complications[J]. Int J Mol Sci,2015,16(12):28418-28428.
[2]	SHAN Y,WANG A,SUN Y,et al.Coagulation and fibrinolytic indices during the first trimester of pregnancy in women with polycystic ovary syndrome:a preliminary study[J]. Reprod Sci,2013,20(11):1390-1397.
[3]	王秋云. 妊娠晚期孕妇血浆D-二聚体水平变化及意义[J]. 中国临床研究,2014,27(3):325-326.
[4]	赵秀萍. 妊娠晚期孕妇检测凝血四项、FDP、D-二聚体的临床意义[J]. 中国妇幼保健,2017,32(5):941-943.
[5]	邓群英,张宏. 妊娠期女性血浆抗凝血酶Ⅲ和D-二聚体参考区间的建立[J]. 检验医学与临床,2016,13(3):341-343.
[6]	毛佩敏,钱蓓蓓,刘晓艳. 孕妇D-二聚体、纤维蛋白(原)降解产物及抗凝血酶参考区间的建立[J]. 检验医学,2017,32(6):471-473.
[7]	刘定华,周子滟,刘欢,等. 重庆地区汉族妊娠晚期女性血浆D-二聚体参考区间的建立[J]. 重庆医学,2016,45(14):1966-1968.
[8]	中华人民共和国卫生部. WS/T 402—2012 临床实验室检验项目参考区间的制定[S]. 北京:中华人民共和国卫生部,2012.
[9]	刁英飞,刘展,冯冬颖,等. 石家庄市4 431例孕产妇妊娠并发症发病率及因素分析[J]. 现代预防医学,2016,43(16):2938-2941.
[10]	LUNG F W,SHU B C,CHIANG T L,et al.Parental mental health,education,age at childbirth and child development from six to 18 months[J]. Acta Paediatr,2009,98(5):834-841.
[11]	叶海雅. 妊娠年龄对妊娠并发症及婴儿成长、智能发育的影响的初步研究[J]. 中国现代医生,2011,49(35):24-26.
[12]	中华人民共和国卫生部. WS/T 359—2011 血浆凝固实验血液标本的采集及处理指南[S]. 北京:中华人民共和国卫生部,2011.

组别	例数	年龄（岁）	AT（%）	DD（μg/mL）
无并发症组	4 548	30.8±4.6	92.3±11.7	1.48（1.03~2.16）
有并发症组
子痫前期	353	31.2±5.1	86.0±14.7^*	1.67（0.97~2.95）^*
ICP	105	29.3±4.1^*	106.3±27.0^*	1.99（1.16~2.67）^*
妊娠期糖尿病	88	32.7±5.2^*	89.4±11.8	1.74（1.21~2.40）^*
死胎	45	29.3±5.0^*	92.6±14.6	2.05（1.29~3.08）^*
DVT	15	30.6±2.8	84.9±17.0	2.24（1.40~2.98）^*

组别	例数	年龄（岁）	AT（%）	DD（μg/mL）
无并发症组	4 548	30.8±4.6	92.3±11.7	1.48（1.03~2.16）
有并发症组
子痫前期	353	31.2±5.1	86.0±14.7^*	1.67（0.97~2.95）^*
ICP	105	29.3±4.1^*	106.3±27.0^*	1.99（1.16~2.67）^*
妊娠期糖尿病	88	32.7±5.2^*	89.4±11.8	1.74（1.21~2.40）^*
死胎	45	29.3±5.0^*	92.6±14.6	2.05（1.29~3.08）^*
DVT	15	30.6±2.8	84.9±17.0	2.24（1.40~2.98）^*

凝血指标	妊娠并发症	阳性预测值（%）	阴性预测值（%）	OR值	95%CI	P值
AT<70%	子痫前期	26.5	93.8	5.41	3.72~7.87	<0.001
	妊娠期糖尿病	1.8	98.6	1.17	0.36~3.74	0.800
	死胎	2.4	98.6	1.68	0.52~5.33	0.410
	DVT	1.9	99.7	4.08	0.93~17.89	0.060
AT>115%	ICP	22.8	98.6	20.24	12.87~31.82	<0.001
DD>3.98 μg/mL	子痫前期	15.6	93.9	2.76	2.01~3.81	<0.001
	妊娠期糖尿病	2.0	98.2	0.65	0.30~1.44	0.289
	死胎	4.2	98.8	4.05	2.16~7.52	<0.001
	DVT	1.5	99.7	5.74	2.03~16.20	0.001
	ICP	5.2	98.2	2.95	1.73~5.02	<0.001

凝血指标	妊娠并发症	阳性预测值（%）	阴性预测值（%）	OR值	95%CI	P值
AT<70%	子痫前期	26.5	93.8	5.41	3.72~7.87	<0.001
	妊娠期糖尿病	1.8	98.6	1.17	0.36~3.74	0.800
	死胎	2.4	98.6	1.68	0.52~5.33	0.410
	DVT	1.9	99.7	4.08	0.93~17.89	0.060
AT>115%	ICP	22.8	98.6	20.24	12.87~31.82	<0.001
DD>3.98 μg/mL	子痫前期	15.6	93.9	2.76	2.01~3.81	<0.001
	妊娠期糖尿病	2.0	98.2	0.65	0.30~1.44	0.289
	死胎	4.2	98.8	4.05	2.16~7.52	<0.001
	DVT	1.5	99.7	5.74	2.03~16.20	0.001
	ICP	5.2	98.2	2.95	1.73~5.02	<0.001

[1]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[2]	HU Bing, LI Gai, ZHANG Huimin. Roles of serum interleukin-6 and D-dimer levels in predicting the risk of cerebral hemorrhage in patients with hypertension [J]. Laboratory Medicine, 2022, 37(1): 63-67.
[3]	DING Ning, ZHANG Weifeng, CHEN Xiaoyong, ZHAO Kewen. Correlations of mean platelet volume,D-dimer and fibrinogen degradation product levels with cerebral infarction and its pathological degree [J]. Laboratory Medicine, 2021, 36(4): 384-387.
[4]	ZHU Chuanxin, ZHOU Yuping, HE Yan, ZHOU Qin. Diagnostic role of NLR,CRP,PCT,DD and NT-proBNP in severe corona virus disease 2019 [J]. Laboratory Medicine, 2021, 36(2): 190-193.
[5]	CHEN Yiming, HUANG Jianxia, SHI Xiaochun, HE Pei, SHEN Yonghai. Diagnostic value of maternal plasma D-dimer and hypertensive disorders of pregnancy in late pregnancy [J]. Laboratory Medicine, 2020, 35(8): 753-756.
[6]	LIU Qin, CHEN Chong, YUE Chao. Role of an elevated D-dimer cut-off value for the prognosis of lung cancer [J]. Laboratory Medicine, 2020, 35(8): 763-766.
[7]	WANG Bin, YUAN Xu, HAN Feng, TANG Ning. Relevant factors on short-term critical events in patients with corona virus disease 2019 [J]. Laboratory Medicine, 2020, 35(6): 540-545.
[8]	CHEN Xing, OU Jingyi, HUANG Ying, TAN Mingkai, CHEN Jiabin, LIN Luping, LIANG Zhiwei, SHI Yaling. Diagnostic roles of several parameters in corona virus disease 2019 [J]. Laboratory Medicine, 2020, 35(4): 295-299.
[9]	zhou YE Ping, DONG Xuemei, ZHANG Chong, DU Xiaozhong. Analysis on the results of coagulation four parameters and D-dimer in healthy pregnant women in Lan [J]. Laboratory Medicine, 2020, 35(4): 334-337.
[10]	MENG Hongbing, CAO Xingjian, FAN Yuping, GU Shuijing, LI Na. Diagnostic value of D-dimer level in different types of pancreatitis [J]. Laboratory Medicine, 2020, 35(3): 260-263.
[11]	ZHENG Wei, HAO Aijun, ZHU Guoyong, ZHANG Yinhui, WANG Dongyun, PANg Jie. Clinical roles of SAA,CRP,LYMPH#,NT-proBNP and DD in COVID-19 [J]. Laboratory Medicine, 2020, 35(12): 1238-1242.
[12]	SHANG Xinrong, CHI Lin, SUI Wenjun. Predictive role of plasma D-dimer and fibrinogen degradation product in pre-eclampsia [J]. Laboratory Medicine, 2020, 35(12): 1252-1254.
[13]	MA Xiuqing, JIA Haiju, QIN Huiping, MA Huiying, YANG Xingtang, QI Yanxia, LI Shengmei, WANG Chunwei, HE Yujuan. Changes of IL-6 and other 7 indexes in patients with acute cerebral infarction in Qinghai [J]. Laboratory Medicine, 2019, 34(9): 821-825.
[14]	CHEN Jie, ZHOU Yujie, ZHAO Menghua, YUAN Yonghua, TAN Chaochao, CAO Youde. Role of laboratory parameters in incomplete Kawasaki disease with coronary artery lesions [J]. Laboratory Medicine, 2019, 34(11): 998-1001.
[15]	CHEN Wenxin, LI Qiang, XUE Yingjun, SHAO Huaqing, LI Zhen, LU Wenqian, HU Xiaobo. Determination of coagulation-fibrinolytic system markers in patients with malignant tumor and its role [J]. Laboratory Medicine, 2018, 33(8): 722-726.